Alnylam Pharmaceuticals

Associate Director, Study Start Up

Alnylam Pharmaceuticals  •  United States (Onsite)  •  15 days ago
Apply
AI can make mistakes so check important info. Chat history is never stored.

Job Description

Overview

Alnylam Pharmaceuticals is seeking a Associate Director, Study Start-up to join our dynamic and growing team.

The Associate Director, Study Start-Up (SSU) provides tactical and operational leadership for assigned studies or programs, with accountability for delivery of end-to-end study start-up activities. This role drives start-up execution, ensures consistent application of SSU processes, and partners cross-functionally to proactively identify risks, resolve issues, and deliver predictable site activation timelines

The Associate Director supports implementation of SSU strategy and process standards while identifying risks, driving issue resolution, and contributing to continuous improvement initiatives.

Key Responsibilities

  • Lead execution of end-to-end study start-up activities for assigned studies, including site feasibility, site selection, regulatory and ethics submissions, site contracting, and site activation.
  • Drive early planning, risk identification, and proactive issue management to support delivery of study start-up timelines.
  • Serve as escalation point for study-level start-up issues, ensuring timely resolution in partnership with cross-functional stakeholders.
  • May provide people leadership for Study Start-Up Managers or SSU Leads, as needed.
  • Ensure consistent application of SSU SOPs, work instructions, job aids, tools, and templates across assigned studies.
  • Contribute to development, refinement, and rollout of SSU processes, tools, and training materials.
  • Drive standardization and best-practice adoption across studies and regions.
  • Monitor and report study-level SSU metrics and KPIs (e.g., site activation timelines, readiness-to-enroll).
  • Use data and insights to identify risks, trends, and opportunities for improvement, escalating as appropriate.
  • Ensure accurate maintenance and use of country and site intelligence to support study planning and execution.
  • Partner with Study Start-up Leadership, Feasibility, Clinical Operations, Clinical Development, Regulatory, Legal, Finance, and CROs to ensure alignment and timely execution of start-up activities.
  • Provide oversight of CRO performance related to study-level start-up deliverables.
  • Support inspection readiness and ensure study start-up activities comply with ICH-GCP, global regulatory requirements, and internal policies and procedures.
  • Participate in continuous improvement initiatives to improve efficiency, quality, and predictability of study start-up.

Qualifications

  • Bachelor’s degree in a healthcare, life sciences, or scientific discipline.
  • Minimum of 8 years of experience in global clinical trial operations and/or study start-up.
  • Minimum of 5 years of people leadership experience, including coaching, performance management, and development of direct reports.
  • Strong understanding of global study start-up processes, regulatory pathways, and site activation models.
  • Demonstrated ability to manage multiple priorities and deliver results in a matrixed environment.
  • Strong analytical, problem-solving, and communication skills.
  • Proven ability to partner cross-functionally and influence without authority.
  • Working knowledge of ICH-GCP and the global regulatory environment.
  • Experience leading complex, multi-regional studies.
  • Experience contributing to process improvement, transformation, or optimization initiatives.
  • Demonstrated success leading and retaining high-performing team members

About Alnylam

We are the leader in RNAi therapeutics – a revolutionary approach with the potential to transform the lives of people with rare and common diseases. Built on Nobel Prize-winning science, Alnylam has delivered the breakthroughs that made RNAi therapeutics possible and are just at the beginning of what’s possible. Our deep pipeline, late-stage programs, and bold vision reflect our core values: fierce innovation, passion for excellence, purposeful urgency, open culture and commitment to people. We're proud to be a globally recognized top employer, where an authentic, inclusive culture and breakthrough thinking fuel one another.

At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. Qualified applicants will receive consideration for employment without regard to their sex, gender or gender identity, sexual orientation, race, color, ethnicity, national origin, ancestry, citizenship, religion, creed, physical or mental disability, pregnancy status or related conditions, genetic information, veteran or military status, marital or familial status, political affiliation, age, or any other factor protected by federal, state, or local law. Alnylam is an E-Verify Employer.

Before applying, please review Alnylam's ⁠Candidate Privacy Notice regarding how Alnylam handles Personal Data you provide with your application for employment.

Alnylam Pharmaceuticals

About Alnylam Pharmaceuticals

SILENCE DISEASE. AMPLIFY LIFE.™

Alnylam is a leading independent biopharmaceutical company and the pioneer in RNA interference (RNAi) therapeutics – a revolutionary approach to treating diseases which “silences” the genes that cause or contribute to them.

Founded in 2002 by a group of distinguished researchers and biotech leaders, Alnylam’s work over more than two decades has yielded the critical breakthroughs and advancements that have made the field of (RNAi) therapeutics possible. In 2018, our first commercial medicine, and the world’s first RNAi therapeutic was approved. Since then, five more Alnylam-developed medicines have been approved and we’re hard at work developing new therapies to treat both rare and prevalent diseases.

We are a global and diverse company of 2,600+ people. We pride ourselves on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we’re consistently ranked as a top employer by The Boston Globe (2015-24), Science Magazine (2018-25), Fast Company (Best Workplaces for Innovators 2020-25) and LinkedIn (2024).

We are based in Cambridge, Massachusetts (U.S.), with offices throughout North America, Europe, Asia, and South America.

See our social media community guidelines: https://bit.ly/2FcRhJy.

Please note: If you wish to report an adverse event or product complaint, please email medinfo@alnylam.com or you may call us using the following telephone numbers: for North America, 877.ALNYLAM (877.256.9526), for Europe, +31 20 369 7861

Fraudulent Recruitment Activity

Be aware of the potential for scams and fraudulent recruitment activity from individuals claiming to represent Alnylam Pharmaceuticals. Alnylam never conducts its interview process via messaging apps, freelance sites, or social media platforms. Alnylam team members only communicate with potential candidates through an official Alnylam email address ending in "@alnylam.com."

Industry
Biotech & Life Sciences
Company Size
1,001-5,000 employees
Headquarters
Cambridge, Massachusetts
Year Founded
2002
Social Media